PTC Therapeutics, Inc.

DB:BH3 Stock Report

Market Cap: €3.4b

PTC Therapeutics Valuation

Is BH3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BH3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€150.10
Fair Value
71.2% undervalued intrinsic discount
14
Number of Analysts

Below Fair Value: BH3 (€43.2) is trading below our estimate of fair value (€150.1)

Significantly Below Fair Value: BH3 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BH3?

Key metric: As BH3 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BH3. This is calculated by dividing BH3's market cap by their current revenue.
What is BH3's PS Ratio?
PS Ratio4x
SalesUS$900.66m
Market CapUS$3.49b

Price to Sales Ratio vs Peers

How does BH3's PS Ratio compare to its peers?

The above table shows the PS ratio for BH3 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.6x
BIO3 Biotest
1.5x3.6%€1.4b
FYB Formycon
15.7x24.6%€962.3m
HPHA Heidelberg Pharma
13.5x16.6%€113.3m
1SXP SCHOTT Pharma KGaA
3.8x9.3%€3.5b
BH3 PTC Therapeutics
4x7.8%€3.5b

Price-To-Sales vs Peers: BH3 is good value based on its Price-To-Sales Ratio (4x) compared to the peer average (8.6x).

Price to Sales Ratio vs Industry

How does BH3's PS Ratio compare vs other companies in the DE Biotechs Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
No. of Companies5PS0612182430+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: BH3 is good value based on its Price-To-Sales Ratio (4x) compared to the European Biotechs industry average (8.6x).

Price to Sales Ratio vs Fair Ratio

What is BH3's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BH3 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4x
Fair PS Ratio2x

Price-To-Sales vs Fair Ratio: BH3 is expensive based on its Price-To-Sales Ratio (4x) compared to the estimated Fair Price-To-Sales Ratio (2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BH3 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€43.20
€55.84
+29.3%
23.2%€72.99€30.73n/a14
Jan ’26€42.80
€55.94
+30.7%
23.7%€76.22€30.49n/a14
Dec ’25€42.40
€43.67
+3.0%
27.3%€64.36€24.61n/a14
Nov ’25€36.40
€38.37
+5.4%
26.3%€59.17€24.04n/a14
Oct ’25€32.80
€35.97
+9.7%
27.7%€57.96€23.55n/a14
Sep ’25€31.80
€35.28
+11.0%
28.8%€57.34€23.29n/a13
Aug ’25€31.00
€35.15
+13.4%
30.8%€56.85€22.92n/a12
Jul ’25€28.40
€36.09
+27.1%
30.3%€57.74€23.28n/a12
Jun ’25€32.60
€33.81
+3.7%
28.2%€48.80€23.02n/a11
May ’25€29.60
€27.58
-6.8%
30.6%€42.07€14.96n/a12
Apr ’25€26.80
€26.77
-0.1%
31.9%€41.42€13.81n/a12
Mar ’25€23.60
€25.99
+10.1%
34.0%€41.53€13.84n/a12
Feb ’25€23.80
€25.58
+7.5%
34.9%€41.45€13.82n/a13
Jan ’25€25.40
€26.07
+2.6%
35.4%€46.46€15.49€42.8013
Dec ’24€20.60
€26.58
+29.0%
35.9%€48.27€16.09€42.4012
Nov ’24€16.90
€26.58
+57.3%
35.9%€48.27€16.09€36.4012
Oct ’24€21.00
€35.09
+67.1%
40.8%€68.46€20.63€32.8012
Sep ’24€35.80
€47.79
+33.5%
21.2%€66.91€32.08€31.8015
Aug ’24€36.00
€48.50
+34.7%
22.0%€66.22€31.75€31.0015
Jul ’24€36.40
€49.55
+36.1%
21.1%€66.90€32.07€28.4015
Jun ’24€38.80
€50.57
+30.3%
21.5%€69.98€32.66€32.6015
May ’24€49.40
€47.73
-3.4%
19.5%€64.43€31.76€29.6015
Apr ’24€44.40
€48.32
+8.8%
19.3%€70.33€32.82€26.8015
Mar ’24€41.80
€48.21
+15.3%
17.6%€62.22€32.99€23.6014
Feb ’24€41.60
€46.15
+10.9%
20.9%€62.32€32.07€23.8014
Jan ’24€34.40
€47.07
+36.8%
21.2%€64.58€32.76€25.4014
Analyst Price Target
Consensus Narrative from 14 Analysts
€54.43
Fair Value
20.6% undervalued intrinsic discount
14
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 10:00
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PTC Therapeutics, Inc. is covered by 27 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Huidong WangBarclays
Geoffrey MeachamBarclays